0000000000173684

AUTHOR

P Schirmacher

showing 3 related works from this author

Drug Treatment for Chronic Hepatitis C Infection and Cancer Risk

2017

BACKGROUND In patients with chronic hepatitis C infection, a sustained virologic response (SVR) to interferon-based therapy markedly decreases the incidence of hepatocellular carcinoma (HCC) over the long term. This is also true for patients who have hepatic cirrhosis, as well as for those with HCC-with or without cirrhosis-who have undergone resection or ablation with curative intent. Recent publications, however, have reported a higher incidence of HCC among patients in both of these subgroups who were treated with direct antiviral agents (DAA) rather than interferon-based therapy. METHODS A selective search for pertinent literature was carried out in the PubMed database with the search t…

medicine.medical_specialtyCarcinoma HepatocellularCirrhosisHepatitis C virusReview Articlemedicine.disease_causeAntiviral AgentsGastroenterology03 medical and health sciencesDrug treatment0302 clinical medicineChronic hepatitisRisk FactorsInterferonInternal medicinemedicineHumansbusiness.industryIncidence (epidemiology)Liver NeoplasmsGeneral MedicineHepatitis C Chronicmedicine.diseasedigestive system diseasesTumor progression030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyNeoplasm Recurrence Localbusinessmedicine.drugDeutsches Ärzteblatt international
researchProduct

Inverse regulation of vascular endothelial growth factor and VHL tumor suppressor gene in sporadic renal cell carcinomas is correlated with vascular …

1999

Tumors associated with the VHL (von Hippel-Lindau) disease, such as hemangioblastomas and renal carcinomas and their sporadic counterparts, are cystic and well vascularized. Mutations of the VHL tumor-suppressor gene and elevated levels of vascular endothelial growth factor (VEGF) have been described in these tumors. The upregulation of VEGF has been shown in vitro as a consequence of alteration of the VHL gene. No comprehensive in vivo analysis has yet been carried out of the factors affecting tumor growth, vascularization, VEGF, and VHL expression. We performed immunohistochemistry and mRNA studies on primary sporadic renal carcinomas and matching normal renal tissue. We semiquantitativel…

AdultMaleVascular Endothelial Growth Factor APathologymedicine.medical_specialtyendocrine system diseasesTumor suppressor geneAngiogenesisUbiquitin-Protein LigasesEndothelial Growth FactorsBiologyurologic and male genital diseasesmedicine.disease_causeLigaseschemistry.chemical_compoundDrug DiscoverymedicineHumansGenes Tumor SuppressorCarcinoma Renal CellGenetics (clinical)AgedLymphokinesKidneyNeovascularization PathologicVascular Endothelial Growth FactorsTumor Suppressor ProteinsProteinsMiddle Agedmedicine.diseaseKidney Neoplasmsfemale genital diseases and pregnancy complicationsGene Expression Regulation NeoplasticVascular endothelial growth factorVascular endothelial growth factor AClear cell renal cell carcinomamedicine.anatomical_structurechemistryVon Hippel-Lindau Tumor Suppressor ProteinMolecular MedicineFemaleCarcinogenesisClear cellJournal of Molecular Medicine
researchProduct

Expression of a dominant negative type II TGF-β receptor in mouse skin results in an increase in carcinoma incidence and an acceleration of carcinoma…

1998

The role of Transforming growth factor beta (TGF-beta) in carcinogenesis is complex. There are reports on both tumor inhibition and tumor promotion by TGF-beta. To elucidate the complex role of TGF-beta in epithelial carcinogenesis, we generated transgenic mice overexpressing a dominant negative type II TGF-beta receptor in the basal cell compartment and in follicular cells of the skin. Despite the reduced responsiveness of transgenic keratinocytes to TGF-beta, both proliferation and differentiation were normal in non-irritated epidermis of these transgenic mice. Thus, interruption of signaling of all three isoforms of TGF-beta in basal and follicular cells does not disturb tissue homeostas…

KeratinocytesCancer Researchmedicine.medical_specialtySkin NeoplasmsRatónMice TransgenicProtein Serine-Threonine KinasesBiologyMiceTransforming Growth Factor betaInternal medicineGene expressionGeneticsCarcinomamedicineAnimalsHumansReceptorMolecular BiologyGeneCells CulturedSkinIncidenceIncidence (epidemiology)Receptor Transforming Growth Factor-beta Type IImedicine.diseaseEndocrinologyTumor progressionCarcinoma Squamous CellCancer researchReceptors Transforming Growth Factor betaCell DivisionSignal TransductionTransforming growth factorOncogene
researchProduct